Trial Profile

Phase I, Interventional, Single Arm, Open Label, Treatment Study to Evaluate The Safety and Tolerability of CLL1-CD33 cCAR in Patients With Relapsed and/or Refractory, High Risk Hematologic Malignancies.

Status: Recruiting

Phase of Trial: Phase I

Latest Information Update: 05 May 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs CLL 1 CD33 cCAR (Primary) ; Cyclophosphamide; Fludarabine
Indications Acute myeloid leukaemia; Haematological malignancies; Myelodysplastic syndromes; Myeloproliferative disorders
Focus Adverse reactions; First in man
Sponsors iCell Gene Therapeutics

17 May 2021 Planned End Date changed from 30 Sep 2020 to 30 Sep 2022.
17 May 2021 Planned primary completion date changed from 30 Sep 2020 to 30 Sep 2022.
21 Jun 2020 Results (n=9) presented at the 25th Congress of the European Haematology Association.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com